Products for Research Use Only

Imiquimod (Standard)

CAT: 0804-HY-B0180R-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0180R-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Imiquimod (Standard) is the analytical standard of Imiquimod. This product is intended for research and analytical applications. Imiquimod (R 837), an immune response modifier, is a selective toll like receptor 7 (TLR7) agonist. Imiquimod exhibits antiviral and antitumor effects in vivo. Imiquimod can be used for the research of external genital, perianal warts, cancer and COVID-19[1][2].
CAS Number
99011-02-6
Product Name Alternative
R 837 (Standard)
UNSPSC
12352005
Hazard Statement
H301-H312-H315-H317-H319-H332-H335
Target
Autophagy; HSV; Reference Standards; SARS-CoV; Toll-like Receptor (TLR)
Type
Reference Standards
Related Pathways
Anti-infection; Autophagy; Immunology/Inflammation; Others
Field of Research
Cancer; Infection; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/imiquimod-standard.html
Smiles
NC1=NC2=CC=CC=C2C3=C1N=CN3CC(C)C
Molecular Formula
C14H16N4
Molecular Weight
240.30
Precautions
P261-P264-P270-P271-P272-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Athina Angelopoulou, et al. Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19. Environ Res. 2020 Sep; 188: 109858.|[2]Aditya K Gupta, et al. Imiquimod: a review. J Cutan Med Surg. Nov-Dec 2002;6 (6) :554-60.|[3]Yuji Kan, et al. Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol. 2012 Oct;86 (19) :10338-46.|[4]Michael P Schön, et al. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion. J Invest Dermatol. 2006 Jun;126 (6) :1338-47.|[5]Leslie van der Fits, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009, 182, 9.|[6]Ajla Smajlović, et al. Molecular and histopathological profiling of imiquimod induced dermatosis in Swiss Wistar rats: contribution to the rat model for novel anti-psoriasis treatments. Mol Biol Rep. 2021, 48, 5.|[7]Sangseo Kim, et al. Development and Optimization of Imiquimod-Loaded Nanostructured Lipid Carriers Using a Hybrid Design of Experiments Approach. Int J Nanomedicine. 2023.
Shipping Conditions
Room temperature
Scientific Category
Reference Standards

Alternative Products

Popular Products